Citius Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2023-12-31; filed 2024-02-14.
0001213900-24-014096
Item 1A. Risk FactorsCurrent report: 10-Q
Period ended 2024-03-31; filed 2024-05-14.
0001213900-24-042920
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 2 previous paragraphs and 8 current paragraphs.
2 unchanged; 0 reworded; 6 added; 0 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (6)
Current report
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Current report
On January 17, 2024, we issued 128,205 shares of our common stock for general and financial advisory services. The issuance of the shares was exempt from registration under Section 4(a)(2) of the Securities Act.
Current report
Item 3. Defaults Upon Senior Securities.